NEW YORK, NY--(Marketwire - December 21, 2009) -
China Aoxing Pharmaceutical Company, Inc.
) ("China Aoxing"), a pharmaceutical company specializing in
research, development, manufacturing and distribution of narcotic and
pain-management products, today announced that it has successfully passed
the Good Manufacturing Practice (GMP) re-certification of four dosage forms,
including capsule, tablet, granule and oral solution formulations, at its
new manufacture and packaging facility. The certificate of compliance has a
five-year term and was issued by the State Food and Drug Administration
(SFDA) following a site inspection.
"Good Manufacturing Practice" is a body of internationally accepted
regulations set forth by drug agencies in many countries. GMP compliance
ensures that pharmaceuticals, active ingredients and medical devices are
produced and quality-controlled according to state-of-the-art standards.
According to the National Medicine Administration Law of the People's
Republic of China, all pharmaceutical manufacturers must pass an
examination every five years to renew their GMP Certificates.
"We are very pleased to obtain the GMP re-certification of four dosage
forms, which is an important milestone in the process of our production
facility consolidation," said Zhenjiang Yue, Chairman and the CEO of China
Aoxing. "The re-certification will serve as a critical step to alleviate
product backlog associated with these dosage forms. In addition, we expect
more GMP re-certification of pill and tincture dosage forms at our brand
new product facility in the first half of year 2010."
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical
company located in China specializing in research, development,
manufacturing and distribution of a variety of narcotics and
pain-management products. Headquartered in Shijiazhuang City, the
pharmaceutical capital of China, outside of Beijing, China Aoxing has
China's largest and the most advanced manufacturing facility for highly
regulated narcotic medicines, addressing a very under-served and
fast-growing market in China. Its facility is one of the few GMP
facilities licensed for narcotics medicines. The Company is working
closely with the Chinese government and SFDA to assure the strictly
regulated availability to medical professionals of its narcotic drugs and
pain medicines throughout China.
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties that may
cause actual results to differ materially from those set forth in these
statements. The economic, competitive, governmental, technological and
other risk factors identified in the Company's filings with the Securities
and Exchange Commission, including the Form 10-KSB for the year ended June
30, 2008, may cause actual results or events to differ materially from
those described in the forward looking statements in this press release.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future
events, or otherwise.